Anabolic therapy in b-thalassaemia major induced osteoporosis: Case report and literature review;La terapia anabolica nella osteoporosi indotta da β-talassemia major: Caso clinico e revisione della letteratura

Reumatismo

Volumn 62, Issue 2, 2010, Pages 119-126

  Trotta, A ^a   Corrado, A ^a   Cantatore, F P ^a  

^a Ospedali Riuniti di Foggia   (Italy)

Author keywords

Osteoporosis; Parathyroid hormone; Spinal fractures; Thalassaemia

Indexed keywords

ALENDRONIC ACID; CALCIFEDIOL; COLECALCIFEROL; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; ANABOLIC AGENT; BONE DENSITY CONSERVATION AGENT; PARATHYROID HORMONE;

ADULT; ARTICLE; BETA THALASSEMIA; CASE REPORT; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; QUALITY OF LIFE; SPINAL PAIN; SPINE FRACTURE; TREATMENT DURATION; BETA-THALASSEMIA; BONE DENSITY; COMPLICATION; DRUG COMBINATION; FEMORAL FRACTURES; LUMBAR VERTEBRA; RISK FACTOR; SPINAL FRACTURES; TREATMENT OUTCOME;

ADULT; ALENDRONATE; ANABOLIC AGENTS; BETA-THALASSEMIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; FEMALE; FEMORAL FRACTURES; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; PARATHYROID HORMONE; RISK FACTORS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 77954883963     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925; 37: 29-34.
2. Wheatherall DJ, Clegg JB. The Thalassaemia Syn dromes. 4th ed. "Oxford": Blackwell Science 2001.
3. Thein SL. Genetic insights into the clinical diversity of b-thalassemia. Br J Haematol 2004; 124: 264-74.
4. Swee LT. Genetic modifiers of b-thalassemia. Haematol J 2005; 90: 649-60.
5. Schrier SL. Pathophysiology of thalassemia. Curr Opin Haematol 2002; 9: 123-6.
6. Thein SL, Al-Hakim I, Hoffbrand AV. Thalassemia intermedia: a new molecular basis. Br J Haematol 1984; 56: 333-7.
7. Saka N, Sukur M, Bundak R, Anak S, Neyzi O, Gedikoglu G. Growth and puberty in thalassemia ma jor. J Pediatr Endocrinol Metab 1995; 8: 181-6.
8. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survi val and complications in thalassemia. Ann NY Acad Sci 2005; 1054: 40-7.
9. Scacchi M, Danesi L, Cattaneo A, Valassi E, Giraldi FP, Argento C, et al. Bone demineralization in adult thalassemic patients. Contribution of growth hormone and insuline-like growth factor I at different sites. Clin Endocrinol 2008; 69: 202-7.
10. Soliman A, Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM. Bone mineral density in prepubertal children with b-thalassemia: correlation with growth and hormonal data. Metabol 1998; 47: 541-8.
11. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, et al. Bone resorption is increased in young adults with thalassemia major. Br J Haematol 2001; 112: 36-41.
12. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hy pogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol 1995; 42: 279-87.
13. Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC. Bone metabolism in thalassemia. Ann NY Acad Sci 1998; 850: 475-8.
14. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicenter study on prevalence of endocrine complication in thalassemia major. Clin Endocrinol 1995; 42: 581-6.
15. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High prevalence of low bone mass in thalassemia major. Br J Haematol 1998; 103: 911-5.
16. Wonke B. Bone disease in b-thalassemia major. Br J Haematol 1998; 103: 897-901.
17. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrin complications in patients with thalassemia major. Pe diatr Endocrinol Rev 2007; 5: 642-8.
18. Kidson-Gerber GL, Francis S, Lindeman R. Man agement and clinical outcomes of transfusion-depen dent thalassemia major in an australian tertiary refer ral clinic. Med Jaust 2008; 188: 72-5.
19. De Virgilis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, et al. Deferoxamine-induced growth retar dation in patients with thalassemia major. J Pediatr 1988; 113: 661-9.
20. Rossi F, Perrotta S, Falcone E, Gimignano F, Iodice M, Vetrella S, et al. Idiopathic and secondary osteo porosis in childhood. Minerva Pediatr 2005; 57: 203-11.
21. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, et al. Growth and develop ment in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996; 155: 368-72.
22. Chan YL, Li CK, Pang LM, Chik KW. Desferriox amine-induced long bone changes in thalassemic pa tient - radiographic features, prevalence and relations with growth. Clin Radiol 2000; 55: 610-14.
23. Resnik D. Diagnosis of bone and joint disorders. In Saunders P (ed). 2002: 2167-76.
24. Consensus Development Conference. Diagnosis, prophilaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
25. Voskaridou E, Terpos E. New insights into the patho physiology and management of osteoporosis in pa tients with thalassaemia major. Br J Haematol 2004; 127: 127-39.
26. Di Stefano M, Chiabotto P, Roggia C, Garofalo F, Lala R, Piga A, et al. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 2004; 22: 53-7.
27. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High incidence of osteo porosis in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11: 975-7.
28. Carmina E, Di Fede G, Napoli N, Renda G, Vitale G, Lo Pinto C, et al. Hypogonadism and hormone re placement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004; 74: 68-71.
29. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, et al. Osteoporosis and b-thalassaemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002; 25: 338-44.
30. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, et al. genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11: 795-801.
31. Origa R, Fiumana E, Gamberoni MR, Armari S, Mottes M, Sangalli A, et al. Osteoporosis in b-tha lassaemia: Clinical and genetic aspects. Ann NY Acad Sci 2005; 1054: 451-6.
32. Borgna-Pignatti C. Thalassemia. A few new titles in a large mosaic. Hematol J. 2006; 91: 1159-62.
33. Pratico G, Di Gregorio F, Caltabiano L, Palano GM, Caruso-Nicoletti M. Calcium phosphate metabolism in thalassemia. Pediatr Med Chir 1998; 20: 265-8.
34. Napoli M, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006; 38: 888-92.
35. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, et al. Osteoporosis in b-tha lassaemia major patients: analysis of the genetic back ground. Br J Haematol 2000; 111: 461-6.
36. Michelson J, Cohen A. Incidence and treatment of fractures in thalassemia. J Orthop Trauma 1988; 2: 29-32.
37. Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, et al. Prevalence of frac tures among the Thalassemia syndromes in North America. Bone 2006; 38: 571-5.
38. Vogiatzi MG, Autio K, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in ado lescents with b-thalassemia. Ann NY Acad Sci 2005; 1054: 462-6.
39. Morabito N, Gaudio A, Lasco A, Atteritano M, Piz zoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of Thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Min er Res 2004; 19: 722-7.
40. Voskaridou E, Terpos E, Spina G, Palermo J, Rahemtulla A, Loutradi A, et al. Pamidronate is an ef fective treatment for osteoporosis in patient with b thalassaemia. Br J Haematol 2003; 123: 730-7.
41. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltzas D, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patient with b-thalassaemia major. J Bone Miner Metab 2007; 25: 60-7.
42. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, et al. The "lively" cytochines network in b-thalassaemia major-related osteoporosis. Bone 2007; 40: 1588-94.
43. Morabito N, Lasco A, Gaudio A, Crisafulli A, di Pietro C, Meo A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002; 13: 644-9.
44. Weinberg ED. Iron loading: a risk factor for osteo porosis. Biometals 2006; 19: 633-5.
45. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. En docrine Rev 1998; 19: 55-79.
46. Brown JP, Josse RG. 2002 clinical practice guide lines for the diagnosis and management of osteo porosis in Canada. CMAJ 2002; 167 (Suppl 10): S1-34.
47. Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, et al. Treatment of b-thalassaemia-associated osteoporosis with zoledronic acid. Br J Haematol 2004; 125: 91-2.
48. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patient with b-thalassaemia: results from a single center, randomised, placebo-controlled trial. Haema tologica. 2006; 91: 1193-2002.
49. Riggs BL, Parfitt AM. Drugs used to treat osteo porosis: the critical need for a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 2005; 20: 177-84.
50. Bilezikian JP. Combination anabolic and antiresorp tive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 2008; 6: 24-30.
51. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 5212-20.
52. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hor mone (1-34)[teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-41.
53. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, et al. Treatment of skeletally ma ture ovariectomized rats with human parathyroid hor mone (1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Min Res 2007; 22: 260-73.
54. McClung M, Miller P, Civitelli R. Differential ef fects of teriparatide and alendronato on markers of bone remodelling and areal and volumetric bone density in women with osteoporosis. Arch Intern Med 2005; 165: 1762-8.
55. Cosman F, Nieves J, Woelfert L. Parathyroid hormone added to estabilished hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16: 925-31.
56. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, et al. Effects of intermittent parathyroid hormone administration on bone miner alization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003; 88: 1150-6.
57. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk re duction after withdrawal of Teriparatide in post menopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
58. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate af ter one year of parathyroid hormone (1-84) for os teoporosis. N Engl J Med 2005; 353: 555-65.
59. Eghbali FG, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANKL in mediating in creased bone resorption in early postmenopausal women. J Clin Invest 2003; 111: 1221-30.
60. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of RANKL regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001; 40: 623-30.
61. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kb ligand (RANKL)/osteprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003; 102: 1064-9.
62. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis in hibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-27.
63. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of continuous Hu man PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprote gerin and gene-associated bone formation. En docrinology 2001; 142: 4047-54.
64. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632-8.
65. Jilca RL, Weinstein RS, Bellido T, Robertson P, Parfitt AM, Manolagas SC. Increased bone forma tion by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
66. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-5.
67. Onyia JE, Gelbert L, Zhang M. Analysis of gene ex pression by DANN microarray reveals novel clues to the mechanism of the catabolic and anabolic actions of PTH in bone (abstract). 23rd Annual Meeting of the ASBMR 2001: F482.
68. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Treschel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone density. N Engl J Med 2002; 346: 653-61.
69. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia Hernandez PA, et al. The effects of intra venous zoledronic acid once yearly on bone remod elling and bone structure. J Bone Miner Res 2007; 23: 6-16.
70. Garnero P. Markers of bone turnover for the predic tion of fracture risk. Osteoporos Int 2000; 11 (Suppl 6): S55-S65.